<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="letter">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Emerg Infect Dis</journal-id>
      <journal-id journal-id-type="publisher-id">EID</journal-id>
      <journal-title-group>
        <journal-title>Emerging Infectious Diseases</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1080-6040</issn>
      <issn pub-type="epub">1080-6059</issn>
      <publisher>
        <publisher-name>Centers for Disease Control and Prevention</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">18044053</article-id>
      <article-id pub-id-type="pmc">2738449</article-id>
      <article-id pub-id-type="publisher-id">06-0699</article-id>
      <article-id pub-id-type="doi">10.3201/eid1305.060699</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Letters to the Editor</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Clindamycin-resistant <italic>Streptococcus pneumoniae</italic></article-title>
        <alt-title alt-title-type="running-head">Clindamycin-resistant <italic>Streptococcus pneumoniae</italic></alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Montagnani</surname>
            <given-names>Francesca</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">*</xref>
          <xref ref-type="aff" rid="aff2">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Zanchi</surname>
            <given-names>Alessandra</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">*</xref>
          <xref ref-type="aff" rid="aff2">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Stolzuoli</surname>
            <given-names>Lucia</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">*</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Croci</surname>
            <given-names>Leonardo</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">*</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Cellesi</surname>
            <given-names>Carla</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">*</xref>
        </contrib>
        <aff id="aff1"><label>*</label>Clinica e Laboratorio di Malattie Infettive, Universit&#xE0; degli Studi di Siena, Italy</aff>
        <aff id="aff2"><label>1</label>Contributed equally to this work.</aff>
      </contrib-group>
      <author-notes>
        <corresp id="cor1">Address for correspondence: Francesca Montagnani, Clinica e Laboratorio di Malattie Infettive, Dipartimento di Biologia Molecolare, Universit&#xE0; di Siena, Ospedale Le Scotte, Piano 0 lotto IV, Viale Bracci, 16, 53100 Siena, Italy; email: <email xlink:href="montagnani2@unisi.it">montagnani2@unisi.it</email></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <month>5</month>
        <year>2007</year>
      </pub-date>
      <volume>13</volume>
      <issue>5</issue>
      <fpage>801</fpage>
      <lpage>802</lpage>
      <kwd-group kwd-group-type="author">
        <title>Keywords: </title>
        <kwd>Streptococcus pneumoniae</kwd>
        <kwd>lincosamide resistance</kwd>
        <kwd>clindamycin resistance</kwd>
        <kwd>new phenotype</kwd>
        <kwd>letter</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <p><bold>To the Editor:</bold> Antimicrobial medications classified as macrolides (e.g., erythromycin) and lincosamides (e.g., clindamycin) show strong activity against streptococci and are commonly used to treat community-acquired infections caused by <italic>Streptococcus pneumoniae</italic>. Moreover, these drugs are the recommended alternatives for patients who cannot tolerate &#x3B2;-lactams.</p>
    <p>Two main macrolide-resistant <italic>S. pneumoniae</italic> phenotypes have been reported (<xref ref-type="bibr" rid="R1"><italic>1</italic></xref>). The first has a high level of resistance to all macrolides, lincosamides, ketolides, and streptogramins B due to ribosomal dimethylation, 23S rRNA mutations, or ribosomal protein mutations (MLS<sub>B</sub>, MS<sub>B</sub>, ML, MKS<sub>B</sub>, and K phenotypes). The second is characterized by a low-level resistance (e.g., MIC 2&#x2013;4 mg/L) to only 14- and 15-member ring macrolides (M phenotype) because of <italic>mef</italic> gene&#x2013;mediated active drug efflux mechanism.</p>
    <p>In January 2005, an erythromycin-susceptible but clindamycin-resistant pneumococcal strain was obtained from a conjunctival swab of a 10-month-old female outpatient attending the daycare center of the Clinic and Laboratory of Infectious Diseases, Siena University, Siena, Italy. To our knowledge, such a phenotype has not been reported in the international literature for <italic>S. pneumoniae</italic>, although a similar phenotype of <italic>Streptococcus agalactiae</italic> was described by Malbruny et al. (<xref ref-type="bibr" rid="R2"><italic>2</italic></xref>).</p>
    <p>The <italic>S. pneumoniae</italic> isolate was identified by standard procedures (<xref ref-type="bibr" rid="R3"><italic>3</italic></xref>) and confirmed by PCR for the common capsule gene <italic>cpsA</italic> (<xref ref-type="bibr" rid="R4"><italic>4</italic></xref>). Serotyping, performed by Quellung reaction, showed a 35F serotype. Susceptibility testing was carried out by disk diffusion and confirmed with E-test according to Clinical and Laboratory Standards Institute standards (<xref ref-type="bibr" rid="R5"><italic>5</italic></xref>,<xref ref-type="bibr" rid="R6"><italic>6</italic></xref>) for penicillin, ceftriaxone, ciprofloxacin, erythromycin, clindamycin, linezolid, and quinupristin-dalfopristin. For telithromycin, because an E-test strip was unavailable, a microbroth diluiton method was used.</p>
    <p>The strain was susceptible to ceftriaxone (MIC 0.125 mg/L), ciprofloxacin (MIC 0.125 mg/L), erythromycin (MIC 0.125 mg/L), linezolid (MIC 1.5 mg/L), quinupristin/dalfopristin (MIC 0.5 mg/L), and telithromycin (MIC &lt;0.0035 mg/L); it was not susceptible to penicillin (MIC 0.125 mg/L) and was resistant to clindamycin (MIC 1 mg/L). A triple disk&#x2013;diffusion test with erythromycin, clindamycin, and josamycin was performed to test resistance inducibility. No inducible pattern was shown.</p>
    <p>To understand the possible resistance mechanism, MICs for 2 lincosamides (clindamycin and lincomycin) were determined by using a microbroth dilution method in the presence and absence of 10 mg/L of the efflux pump inhibitor reserpine (Sigma Chemicals, St Louis, MO, USA), as described (<xref ref-type="bibr" rid="R7"><italic>7</italic></xref>); <italic>S</italic>. <italic>pneumoniae</italic> ATCC 49619 and <italic>S</italic>. <italic>mitis</italic> 21A29 (<italic>mefE</italic><sup>+</sup>) were used as controls (<xref ref-type="bibr" rid="R8"><italic>8</italic></xref>). The MICs remained unchanged in the presence of reserpine: 1 mg/L for clindamycin and 4 mg/L for lincomycin.</p>
    <p>The strain was screened for <italic>erm</italic>TR, <italic>erm</italic>B or <italic>mef</italic>A, and <italic>mef</italic>E determinants as described (<xref ref-type="bibr" rid="R8"><italic>8</italic></xref>,<xref ref-type="bibr" rid="R9"><italic>9</italic></xref>). All PCR controls gave the expected results. No PCR product was obtained for the studied isolate.</p>
    <p>Preliminary data did not show classic macrolide resistance determinants for <italic>S. pneumoniae</italic>. Low-level lincosamide resistance suggests the presence of some efflux mechanism, even if no inhibition by reserpine was observed. Moreover, no mutations of ribosomal proteins and of known binding sites for lincosamides in rRNA (<xref ref-type="bibr" rid="R1"><italic>1</italic></xref>) were shown by sequencing of L22, L4, and 23S rRNA domain II and V genes with primers described by Canu et al. (<xref ref-type="bibr" rid="R10"><italic>10</italic></xref>). Although these findings are preliminary and the molecular basis for resistance is the subject of ongoing investigation, the identification of this <italic>S. pneumoniae</italic> phenotype may affect clinical management of pneumococcal infections, especially in the treatment of patients intolerant of &#x3B2;-lactams.</p>
  </body>
  <back>
    <fn-group>
      <fn fn-type="citation">
        <p>Suggested citation for this article: Montagnani F, Zanchi A, Stolzuoli L, Croci L, Cellesi C. Clindamycin-resistant <italic>Streptococcus pneumoniae</italic> [letter]. Emerg Infect Dis [serial on the Internet]. 2007 May [date cited]. Available from <ext-link ext-link-type="uri" xlink:href="http://www.cdc.gov/eid/content/13/5/801.htm">http://www.cdc.gov/eid/content/13/5/801.htm</ext-link></p>
      </fn>
    </fn-group>
    <ack>
      <title>Acknowledgments</title>
      <p>We thank Dr. Elisabetta Mantengoli for useful suggestion on gene sequencing and Sanofi Aventis for providing telithromycin.</p>
      <p>Strain serotyping was performed at Streptococcal Reference Unit of Respiratory and Systemic Infection Laboratory, Centre for Infections, Health Protection Agency, London, UK.</p>
    </ack>
    <ref-list>
      <title>References</title>
      <ref id="R1">
        <label>1. </label>
        <mixed-citation publication-type="journal"><string-name><surname>Edelstein</surname> <given-names>PH</given-names></string-name> <article-title>Pneumococcal resistance to macrolides, lincosamides, ketolides, and streptogramin B agents: molecular mechanisms and resistance phenotype.</article-title><source>Clin Infect Dis</source> <year>2004</year>;<volume>38</volume>:<fpage>S322</fpage>&#x2013;<lpage>7</lpage> <pub-id pub-id-type="doi">10.1086/382687</pub-id><pub-id pub-id-type="pmid">15127365</pub-id></mixed-citation>
      </ref>
      <ref id="R2">
        <label>2. </label>
        <mixed-citation publication-type="journal"><string-name><surname>Malbruny</surname> <given-names>B</given-names></string-name>, <string-name><surname>Werno</surname> <given-names>AM</given-names></string-name>, <string-name><surname>Anderson</surname> <given-names>TP</given-names></string-name>, <string-name><surname>Murdroch</surname> <given-names>DR</given-names></string-name>, <string-name><surname>Leclercq</surname> <given-names>R</given-names></string-name> <article-title>A new phenotype of resistance to lincosamide and streptogramin A-type antibiotics in <italic>Streptococcus agalactiae</italic> in New Zealand.</article-title><source>J Antimicrob Chemother</source> <year>2004</year>;<volume>54</volume>:<fpage>1040</fpage>&#x2013;<lpage>4</lpage> <pub-id pub-id-type="doi">10.1093/jac/dkh493</pub-id><pub-id pub-id-type="pmid">15537693</pub-id></mixed-citation>
      </ref>
      <ref id="R3">
        <label>3. </label>
        <mixed-citation publication-type="book"><string-name><surname>Rouff</surname> <given-names>KL</given-names></string-name>, <string-name><surname>Whiley</surname> <given-names>RA</given-names></string-name>, <string-name><surname>Beighton</surname> <given-names>D</given-names></string-name> Streptococcus. In: Murray PR, Baron EJ, Jorgensen JH, Pfaller MA, Yolken RH, editors. Manual of clinical microbiology. 8th ed. Washington: American Society for Microbiology; <year>2003</year> p. 405&#x2013;21.</mixed-citation>
      </ref>
      <ref id="R4">
        <label>4. </label>
        <mixed-citation publication-type="journal"><string-name><surname>Lawrence</surname> <given-names>ER</given-names></string-name>, <string-name><surname>Griffiths</surname> <given-names>DB</given-names></string-name>, <string-name><surname>Martin</surname> <given-names>SA</given-names></string-name>, <string-name><surname>George</surname> <given-names>RC</given-names></string-name>, <string-name><surname>Hall</surname> <given-names>LM</given-names></string-name> <article-title>Evaluation of semiautomated multiplex PCR assay for determination of <italic>Streptococcus pneumoniae</italic> serotypes and serogroups.</article-title><source>J Clin Microbiol</source> <year>2003</year>;<volume>41</volume>:<fpage>601</fpage>&#x2013;<lpage>17</lpage> <pub-id pub-id-type="doi">10.1128/JCM.41.2.601-607.2003</pub-id><pub-id pub-id-type="pmid">12574253</pub-id></mixed-citation>
      </ref>
      <ref id="R5">
        <label>5. </label>
        <mixed-citation publication-type="book"><collab>Clinical and Laboratory Standards Institute</collab> Performance standards for antimicrobial disk susceptibility tests, 9th ed. Approved standard M2&#x2013;A9. Wayne (PA): The Institute; <year>2006</year></mixed-citation>
      </ref>
      <ref id="R6">
        <label>6. </label>
        <mixed-citation publication-type="other"><collab>Clinical and Laboratory Standards Institute</collab> Performance standards for antimicrobial susceptibility testing, 16th Informational Suppl. M100&#x2013;S16. Wayne (PA): The Institute; <year>2006</year></mixed-citation>
      </ref>
      <ref id="R7">
        <label>7. </label>
        <mixed-citation publication-type="journal"><string-name><surname>Brenwald</surname> <given-names>NP</given-names></string-name>, <string-name><surname>Martin</surname> <given-names>JG</given-names></string-name>, <string-name><surname>Wise</surname> <given-names>R</given-names></string-name> <article-title>Prevalence of a putative efflux mechanism among fluoroquinolone-resistant clinical isolates of <italic>Streptococcus pneumoniae.</italic></article-title><source>Antimicrob Agents Chemother</source> <year>1998</year>;<volume>42</volume>:<fpage>2032</fpage>&#x2013;<lpage>5</lpage><pub-id pub-id-type="pmid">9687402</pub-id></mixed-citation>
      </ref>
      <ref id="R8">
        <label>8. </label>
        <mixed-citation publication-type="journal"><string-name><surname>Oster</surname> <given-names>P</given-names></string-name>, <string-name><surname>Zanchi</surname> <given-names>A</given-names></string-name>, <string-name><surname>Cresti</surname> <given-names>S</given-names></string-name>, <string-name><surname>Lattanzi</surname> <given-names>M</given-names></string-name>, <string-name><surname>Montagnani</surname> <given-names>F</given-names></string-name>, <string-name><surname>Cellesi</surname> <given-names>C</given-names></string-name>, <etal/><article-title>Patterns of macrolide resistance determinants among community-acquired <italic>Streptococcus pneumoniae</italic> isolates over a 5-year period of decreased macrolide susceptibility rates.</article-title><source>Antimicrob Agents Chemother</source> <year>1999</year>;<volume>43</volume>:<fpage>2510</fpage>&#x2013;<lpage>2</lpage><pub-id pub-id-type="pmid">10508033</pub-id></mixed-citation>
      </ref>
      <ref id="R9">
        <label>9. </label>
        <mixed-citation publication-type="journal"><string-name><surname>Cresti</surname> <given-names>S</given-names></string-name>, <string-name><surname>Lattanzi</surname> <given-names>M</given-names></string-name>, <string-name><surname>Zanchi</surname> <given-names>A</given-names></string-name>, <string-name><surname>Montagnani</surname> <given-names>F</given-names></string-name>, <string-name><surname>Pollini</surname> <given-names>S</given-names></string-name>, <string-name><surname>Cellesi</surname> <given-names>C</given-names></string-name>, <etal/><article-title>Resistance determinants and clonal diversity in group A streptococci collected during a period of increasing macrolide resistance.</article-title><source>Antimicrob Agents Chemother</source> <year>2002</year>;<volume>46</volume>:<fpage>1816</fpage>&#x2013;<lpage>22</lpage> <pub-id pub-id-type="doi">10.1128/AAC.46.6.1816-1822.2002</pub-id><pub-id pub-id-type="pmid">12019095</pub-id></mixed-citation>
      </ref>
      <ref id="R10">
        <label>10. </label>
        <mixed-citation publication-type="journal"><string-name><surname>Canu</surname> <given-names>A</given-names></string-name>, <string-name><surname>Malbruny</surname> <given-names>B</given-names></string-name>, <string-name><surname>Coquemont</surname> <given-names>N</given-names></string-name>, <string-name><surname>Davies</surname> <given-names>TA</given-names></string-name>, <string-name><surname>Appelbaum</surname> <given-names>PC</given-names></string-name>, <string-name><surname>Leclercq</surname> <given-names>R</given-names></string-name> <article-title>Diversity of ribosomal mutations conferring resistance to macrolides, clindamycin, streptogramin, and telithromycin in <italic>Streptococcus pneumoniae.</italic></article-title><source>Antimicrob Agents Chemother</source> <year>2002</year>;<volume>46</volume>:<fpage>125</fpage>&#x2013;<lpage>31</lpage> <pub-id pub-id-type="doi">10.1128/AAC.46.1.125-131.2002</pub-id><pub-id pub-id-type="pmid">11751122</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
